Cadherin expression in ovarian carcinoma and malignant mesothelioma cell effusions

Acta Cytologica

Volumn 50, Issue 6, 2006, Pages 603-607

  Sivertsen, Stine ^a   Berner, Aasmund ^a   Michael, Claire W ^b   Bedrossian, Carlos ^c   Davidson, Ben ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c Norwegian American Hospital   (United States)

Author keywords

Cadherins; Carcinoma, ovarian; Carcinoma, primary peritoneal; Mesothelioma

Indexed keywords

CADHERIN; NERVE CELL ADHESION MOLECULE; P CADHERIN; UNCLASSIFIED DRUG; UVOMORULIN;

ARTICLE; CELL ADHESION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; MAJOR CLINICAL STUDY; MALIGNANT MESOTHELIOMA; OVARY CARCINOMA; PERITONEUM EXUDATE; PLEURA EFFUSION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 33751171065     PISSN: 00015547     EISSN: 19382650     Source Type: Journal    
DOI: 10.1159/000326027     Document Type: Article

References (31)

1. Takeichi M: The cadherins: Cell-cell adhesion molecules controlling animal morphogenesis. Development 1988;102:639-655
2. Shirayoshi Y, Hatta K, Hosoda M, Tsunasawa S, Sakiyama F, Takechi M: Cadherin cell adhesion molecules with distinct binding specificities share a common structure. EMBO J 1986;5:2485-2488
3. Takeichi M: Cadherin cell adhesion receptors as a morphogenetic regulator. Science 1991;51:1451-1455
4. Shiozaki H, Oka H, Inoue M, Tamura S, Monden M: E-cadherin mediated adhesion system in cancer cells. Cancer 1996;77:1605-1613
5. Hirohashi S: Inactivation of the E-cadherin-mediated cell adhesion system in human cancers. Am J Pathol 1998;153:333-339
6. Oka H, Shiozaki H, Kobayashi K, Tahara H, Tamura S, Miyata M, Dold Y, Iihara K, Matsuyoshi N, Hirano S, et al: Immunohistochemical evaluation of E-cadherin adhesion molecule expression in human gastric cancer. Virchows Arch A Pathol Anat Histopathol 1992;421:149-156
7. Bukholm IK, Nesland JM, Børresen-Dale AL: Re-expression of E-cadherin, α-catenin and β-catenin, but not γ-catenin, in metastatic tissue from breast cancer patients. J Pathol 2000;190:15-19
8. Davidson B, Berner A, Nesland JM, Risberg B, Berner HS, Trope CG, Kristensen GB, Bryne M, Ann Florenes V: E-cadherin and α-, β- and γ-catenin protein expression is up-regulated in ovarian carcinoma cells in serous effusions. J Pathol 2000;192:460-469
9. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Gahfoor A, Feuer EJ, Thun MJ, American Cancer Society: Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30
10. Britton M: The epidemiology of mesothelioma. Semin Oncol 2002;29:18-25
11. Feldman AL, Libutti SK, Pingpank JF, Bartlett DL, Beresnev TH, Mavroukakis SM, Steinburg SM, Liewehr DJ, Kleiner DE, Alexander HR: Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol 2003;21:4560-4567
12. Bedrossian CWM: Diagnostic problems in serous effusions. Diagn Cytopathol 1998;19:131-137
13. Davidson B, Nielsen S, Christensen J, Asschenfeldt P, Berner A, Risberg B, Johansen P: The role of desmin and N-cadherin in effusion cytology: A comparative study using established markers of mesothelial and epithelial cells. Am J Surg Pathol 2001;25:1405-1412
14. Ordonez NG: Role of immunohistochemistry in distinguishing epithelial peritoneal mesotheliomas from peritoneal and ovarian serous carcinomas. Am J Surg Pathol 1998;22:1203-1214
15. Bedrossian CW: Special stains, the old and the new: The impact of immunocytochemistry in effusion cytology. Diagn Cytopathol 1998;18:141-149
16. Scharnhorst V, van der Eb AJ, Jochemsen AG: WT1 proteins: Functions in growth and differentiation. Gene 2001;273:141-161
17. Kumar-Singh S, Segers K, Rodeck U, Backhovens H, Bogers J, Weyler J, Van Broeckhoven C, Van Marck E: WT1 mutation in malignant mesothelioma and WT1 immunoreactivity in relation to p53 and growth factor receptor expression, cell-type transition, and prognosis. J Pathol 1997;181:67-74
18. Waldstrom M, Grove A: Immunohistochemical expression of Wilms tumor gene protein in different histologic subtypes of ovarian carcinomas. Arch Pathol Lab Med 2005;129:85-88
19. Drapkin R, Crum CP, Hecht JL: Expression of candidate tumor markers in ovarian carcinoma and benign ovary: Evidence for a link between epithelial phenotype and neoplasia. Hum Pathol 2004;35:1014-1021
20. Bassarova AV, Nesland JM, Davidson B: D2-40 is not a specific marker for cells of mesothelial origin in serous effusions. Am J Surg Pathol (submitted for publication)
21. Pisharodi LR, Bedrossian CW: Cytopathology of serous neoplasia of the ovary and the peritoneum: Differential diagnosis from mesothelial proliferations. Diagn Cytopathol 1996;15:292-295
22. Sivertsen S, Hadar R, Elloul S, Vintman L, Bedrossian C, Reich R, Davidson B: Expression of Snail, Shug and Sip 1 in malignant mesothelioma effusions is associated with matrix metalloproteinase, but not with cadherin expression. Lung Cancer (submitted for publication)
23. Han AC, Peralta Soler A, Knudsen KA, Wheelock MJ, Johnson KR, Salazar H: Differential expression of N-cadherin in pleural mesotheliomas and E-cadherin in lung adenocarcinomas in formalin-fixed, paraffin-embedded tissues. Hum Pathol 1997;28:641-645
24. Han AC, Filstein MR, Hunt JV, Solar AP, Knudsen KA, Salazar H: N-cadherin distinguishes pleural mesotheliomas from lung adenocarcinomas: A ThinPrep, immunocytochemical study. Cancer Cytopathol 1999;87:83-86
25. Peralta Soler A, Knudsen KA, Jaurand MC, Johnson KR, Wheelock MJ, Klein-Szanto AJ, Salazar H: The differential expression of N-cadherin and E-cadherin distinguishes pleural mesotheliomas from lung adenocarcinomas. Hum Pathol 1995;26:1363-1369
26. Leers MP, Aarts MM, Theunissen PH: E-cadherin and calretinin: A useful combination of immunochemical markers for differentiation between mesothelioma and metastatic adenocarcinoma. Histopathology 1998;32:209-216
27. Schofield K, D'Aquila T, Rimm DL: The cell adhesion molecule, E-cadherin, distinguishes mesothelial cells from carcinoma cells in fluids. Cancer 1997;81:293-298
28. Simsir A, Fetsch P, Mehta D, Zakowski M, Abati A: E-cadherin, N-cadherin, and calretinin in pleural effusions: The good, the bad, the worthless. Diagn Cytopathol 1999;20:125-130
29. Kitazume H, Kitamura K, Mukai K, Inayama Y, Kawano N, Nakamura N, Sano J, Mitsui K, Yoshida S, Nakatani Y: Cytologic differential diagnosis among reactive mesothelial cells, malignant mesothelioma, and adenocarcinoma. Cancer Cytopathol 2000;90:55-60
30. Patel IS, Madan P, Getsios S, Bertrand MA, MacCalman CD: Cadherin switching in ovarian cancer progression. Int J Cancer 2003;106:172-177
31. Orecchia S, Schillaci F, Salvio M, Libener R, Betta PG: Aberrant E-cadherin and gamma-catenin expression in malignant mesothelioma and its diagnostic and biological relevance. Lung Cancer (suppl 1) 2004;45:S37-S43